| 영문 | dopamine | 한글 | 도파민 |
|---|---|---|---|
| 설명 | 히드록시티라민으로서 생리활성 아민-카테콜아민의 일종. 분자식은C18H11NO2, 분자량은 153.18이다. 동식물에 존재하는 아미노산의 하나로, 자외선 작용으로 티로신에서 형성되거나 L-Dopa의 탈탄산에 의해 체내에서 생산된다. 멜라닌 색소 합성 과정의 중간 물질로 콩과 식물에 저장되어 있다. 뇌신경 세포의 흥분 전달에 중요한 구실을 한다. 도파민β-산화효소의 작용에 의해 노르아드레날린이 된다. 부신수질-뇌-교감신경계-폐-작은창자-간 등에도 많이 포함되어 있다. 파킨슨 증후군의 경우 뇌 안의 도파민 량이 감소되며, 뇌줄기의 줄무늬체에는 노르아드레날린보다 도파민이 다량 포함되어 있음을 볼 수 있다는 점에서 도파민 자체가 이른바 카테콜아민을 함유하는 작동성 뉴런의 신경전달물질로서 작용하고 있음이 분명해졌다. |
||
| H0 | null hypothesis |
|---|---|
| H1 | alternative hypothesis |
| LNH | large number hypothesis |
| TRH | tension-reducing hypothesis; thyrotropin-releasing hormone |
| DBH | Dopamine-Beta(β)-Hydroxylase |
| (3)H | hypothesis that |
|---|---|
| DA | 14C-dopamine |
| DA | 3)H]-dopamine |
| [(3)H]-DA | 3)H]-dopamine |
| dopamine | 3,4-Dihydroxyphenylethylamine |
striate body neurosis
| receptors, dopamine | Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
|---|---|
| receptors, dopamine d1 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action. (12 Dec 1998) |
| receptors, dopamine d2 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action. (12 Dec 1998) |
| dopamine | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| dopamine beta-hydroxylase | <enzyme> Chemical name: 3,4-Dihydroxyphenethylamine, ascorbate:oxygen oxidoreductase (beta-hydroxylating) Registry number: EC 1.14.17.1 (12 Dec 1998) |
| dopamine beta-monooxygenase | A copper-containing enzyme catalyzing oxidation of ascorbate and 3,4-dihydroxyphenylethylamine simultaneously by O2 to yield norepinephrine, dehydroascorbate, and water; a crucial step in catecholamine metabolism. Synonym: dopamine beta-hydroxylase. (05 Mar 2000) |
| dopamine hydrochloride | A biogenic amine and neural transmitter substance, used as a vasopressor agent for treatment of shock. (05 Mar 2000) |
| dopamine uptake inhibitors | Drugs that block the transport of dopamine into axon terminals or into storage vesicles within terminals. most of the adrenergic uptake inhibitors also inhibit dopamine uptake. (12 Dec 1998) |
| adaptor hypothesis | A hypothesis, proposed by F.H.C. Crick, that an adaptor molecule must be present between the information-containing DNA and the protein being synthesised. (05 Mar 2000) |
| altered self hypothesis | The hypothesis that the T-cell receptor in MHC mediated phenomena recognises a syngeneic MHC Class I or Class II molecule after modification by a virus or certain chemicals. See: MHC restriction. (18 Nov 1997) |
| alternative hypothesis | In Neyman-Pearson testing of a hypothesis, the hypothesis or family of hypotheses about the numerical value of a parameter if and only if the null hypothesis is rejected as untenable. (05 Mar 2000) |
| autocrine hypothesis | That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|